[go: up one dir, main page]

AR102712A1 - Agonistas parciales del receptor de insulina - Google Patents

Agonistas parciales del receptor de insulina

Info

Publication number
AR102712A1
AR102712A1 ARP150103770A ARP150103770A AR102712A1 AR 102712 A1 AR102712 A1 AR 102712A1 AR P150103770 A ARP150103770 A AR P150103770A AR P150103770 A ARP150103770 A AR P150103770A AR 102712 A1 AR102712 A1 AR 102712A1
Authority
AR
Argentina
Prior art keywords
partial agonists
insulin receptor
receptor partial
insulin
dimers
Prior art date
Application number
ARP150103770A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR102712A1 publication Critical patent/AR102712A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se divulgan dímeros de insulina y dímeros de análogo de insulina que actúan como agonistas parciales en el receptor de insulina. Composición. Procedimiento para tratar la diabetes. Uso. Compuesto.
ARP150103770A 2014-11-21 2015-11-19 Agonistas parciales del receptor de insulina AR102712A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462082857P 2014-11-21 2014-11-21
US201562242503P 2015-10-16 2015-10-16

Publications (1)

Publication Number Publication Date
AR102712A1 true AR102712A1 (es) 2017-03-22

Family

ID=54838417

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103770A AR102712A1 (es) 2014-11-21 2015-11-19 Agonistas parciales del receptor de insulina

Country Status (26)

Country Link
US (4) US20170355743A1 (es)
EP (4) EP3660040B1 (es)
JP (5) JP6484337B2 (es)
KR (2) KR102049647B1 (es)
CN (2) CN108064173B (es)
AR (1) AR102712A1 (es)
AU (3) AU2015349890B2 (es)
CA (2) CA3014641C (es)
CL (3) CL2017001288A1 (es)
CO (1) CO2017004976A2 (es)
CR (1) CR20170208A (es)
DO (1) DOP2017000124A (es)
EA (1) EA036714B1 (es)
ES (2) ES3004386T3 (es)
GT (1) GT201700104A (es)
IL (1) IL252257A0 (es)
MX (3) MX2017006651A (es)
NI (1) NI201700060A (es)
PE (1) PE20170957A1 (es)
PH (1) PH12017500935A1 (es)
SG (4) SG10201809427SA (es)
SV (1) SV2017005445A (es)
TN (1) TN2017000178A1 (es)
TW (1) TW201625673A (es)
WO (1) WO2016081670A2 (es)
ZA (1) ZA201703238B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201700777VA (en) 2014-08-04 2017-02-27 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
TW201625673A (zh) 2014-11-21 2016-07-16 默沙東藥廠 胰島素受體部分促效劑
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
EP3922260A3 (en) * 2016-05-24 2022-06-15 Merck Sharp & Dohme Corp. Insulin receptor partial agonists and glp-1 analogues
US10689430B2 (en) 2016-05-25 2020-06-23 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
WO2018077851A1 (en) * 2016-10-24 2018-05-03 Novo Nordisk A/S Bioassay for insulin formulations
WO2019034726A1 (en) 2017-08-17 2019-02-21 Novo Nordisk A/S NOVEL ACYLATED INSULIN ANALOGUES AND USES THEREOF
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
CN112898172B (zh) * 2019-12-04 2022-05-31 中国科学院大连化学物理研究所 可被羧肽酶酶解的双亲和功能团化合物的合成方法
US11685727B2 (en) 2019-12-20 2023-06-27 Nuevolution A/S Compounds active towards nuclear receptors
JP2021098692A (ja) 2019-12-20 2021-07-01 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ 核内受容体に対して活性の化合物
JP7713954B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
MX2022012260A (es) 2020-03-31 2022-11-30 Nuevolution As Compuestos activos frente a receptores nucleares.
EP4204441A4 (en) * 2020-08-26 2025-01-08 Merck Sharp & Dohme LLC Insulin receptor partial agonists
WO2022046747A1 (en) * 2020-08-26 2022-03-03 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
EP4208173A4 (en) * 2020-09-03 2025-11-26 Dyne Therapeutics Inc PROCESSES FOR PREPARING PROTEIN-OLIGONUCLEOTIC COMPLEXES
CN116457015A (zh) * 2020-09-03 2023-07-18 达因疗法公司 制备蛋白质-寡核苷酸复合物的方法
EP4210729A4 (en) * 2020-09-09 2025-01-01 Merck Sharp & Dohme LLC PARTIAL INSULIN RECEPTOR AGONISTS
US11672872B2 (en) 2021-07-09 2023-06-13 Dyne Therapeutics, Inc. Anti-transferrin receptor antibody and uses thereof
EP4366784A1 (en) 2021-07-09 2024-05-15 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11633498B2 (en) 2021-07-09 2023-04-25 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
AU2023254846A1 (en) 2022-04-15 2024-10-10 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating myotonic dystrophy

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3907763A (en) 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5304473A (en) 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
AU1272295A (en) 1993-12-17 1995-07-03 Novo Nordisk A/S Proinsulin-like compounds
CA2223272A1 (en) 1995-05-05 1996-11-07 Ronald Eugene Chance Single chain insulin with high bioactivity
CA2318806A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding agents that modulate the 5-ht transporter
DE19908041A1 (de) * 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
AU2002248464A1 (en) 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
US7105314B2 (en) 2001-04-02 2006-09-12 Novo Nordisk A/S Method for making human insulin precursors
DK2226316T3 (en) 2002-05-30 2016-04-11 Scripps Research Inst Copper catalyzed ligation of azides and acetylenes
KR100507796B1 (ko) 2003-04-03 2005-08-17 한미약품 주식회사 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
AU2004295023A1 (en) 2003-12-03 2005-06-16 Novo Nordisk A/S Single-chain insulin
WO2006045710A2 (en) 2004-10-27 2006-05-04 Novo Nordisk A/S Insulin receptor binding peptides with non-insulin gene activation profiles and uses thereof
US7807619B2 (en) 2004-11-01 2010-10-05 The Regents Of The University Of California Compositions and methods for modification of biomolecules
JP2008533100A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｐｅｇ化された単鎖インスリン
EP1991575A1 (en) 2006-02-21 2008-11-19 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
WO2007104737A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104734A1 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
WO2007104736A2 (en) 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
US20090099065A1 (en) 2006-03-13 2009-04-16 Novo Nordisk A/S Acylated Single Chain Insulin
WO2008019368A2 (en) 2006-08-07 2008-02-14 Teva Biopharmaceuticals Usa, Inc. Albumin-insulin fusion proteins
WO2008145721A2 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S N-terminal modification of polypeptides for protection against degradation by aminopeptidases
JP2011511778A (ja) 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
KR20110021758A (ko) 2008-04-22 2011-03-04 케이스 웨스턴 리저브 유니버시티 이형체-특이적 인슐린 유사체
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
LT2349324T (lt) * 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
CN102245624B (zh) 2008-12-19 2016-08-10 印第安纳大学研究及科技有限公司 基于酰胺的胰岛素前药
WO2011059895A1 (en) 2009-11-11 2011-05-19 Quest Diagnostics Investments Incorporated Hexa mutations
AU2011268327B2 (en) 2010-06-16 2016-02-25 Indiana University Research And Technology Corporation Single chain insulin agonists exhibiting high activity at the insulin receptor
US8255297B2 (en) 2010-07-20 2012-08-28 Facebook, Inc. Creation, redemption, and accounting in a virtual currency system
CN103154024A (zh) 2010-10-15 2013-06-12 诺沃—诺迪斯克有限公司 新型n末端修饰的胰岛素衍生物
CN104010652A (zh) * 2011-10-27 2014-08-27 卡斯西部储备大学 超浓缩的速效胰岛素类似物制剂
WO2014052451A2 (en) * 2012-09-26 2014-04-03 Indiana University Research And Technology Corporation Insulin analog dimers
EP2968472A1 (en) 2013-03-15 2016-01-20 Université de Genève Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production
US9884125B2 (en) * 2013-10-04 2018-02-06 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
US10758636B2 (en) * 2013-11-12 2020-09-01 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
PE20161153A1 (es) 2014-01-20 2016-10-27 Hanmi Pharm Ind Co Ltd Insulina de accion prolongada y uso de la misma
TW201625673A (zh) * 2014-11-21 2016-07-16 默沙東藥廠 胰島素受體部分促效劑

Also Published As

Publication number Publication date
BR112017010481A2 (pt) 2018-04-03
JP2020097572A (ja) 2020-06-25
IL252257A0 (en) 2017-07-31
SG10201809427SA (en) 2018-11-29
AU2018211208B2 (en) 2020-09-10
SG10201809457YA (en) 2018-11-29
JP6484337B2 (ja) 2019-03-13
EP3660041A1 (en) 2020-06-03
AU2015349890B2 (en) 2018-08-30
ES3004386T3 (en) 2025-03-12
US10017556B2 (en) 2018-07-10
JP2019011357A (ja) 2019-01-24
JP6943825B2 (ja) 2021-10-06
EP3660040B1 (en) 2025-06-18
PE20170957A1 (es) 2017-07-13
MX2017006651A (es) 2017-08-21
KR102049647B1 (ko) 2019-11-29
JP2019014734A (ja) 2019-01-31
ZA201703238B (en) 2018-05-30
CR20170208A (es) 2017-07-17
CN112494656B (zh) 2024-01-30
EP3666792A2 (en) 2020-06-17
JP6931033B2 (ja) 2021-09-01
AU2018211207A1 (en) 2018-08-16
CL2017001288A1 (es) 2017-12-15
EA036714B1 (ru) 2020-12-10
US10800827B2 (en) 2020-10-13
CA3014641C (en) 2020-08-18
MX2020014121A (es) 2021-03-25
ES2946247T3 (es) 2023-07-14
TW201625673A (zh) 2016-07-16
SG11201704064TA (en) 2017-06-29
US20180291078A1 (en) 2018-10-11
BR122024000898A2 (pt) 2024-02-27
US20170355743A1 (en) 2017-12-14
BR122024000903A2 (pt) 2024-02-27
KR20170084300A (ko) 2017-07-19
NI201700060A (es) 2017-07-18
SV2017005445A (es) 2018-04-04
US20190092833A1 (en) 2019-03-28
US20170107268A1 (en) 2017-04-20
CL2019001143A1 (es) 2019-07-19
CN108064173B (zh) 2021-05-18
EP3666792B1 (en) 2024-12-18
EP3221343B1 (en) 2020-09-16
EA201791117A1 (ru) 2017-11-30
EP3660040A2 (en) 2020-06-03
EP3666792A3 (en) 2020-07-29
CA3014641A1 (en) 2016-05-26
SG10201809428UA (en) 2018-11-29
AU2015349890A1 (en) 2017-06-01
EP3660040A3 (en) 2020-07-29
AU2018211207B2 (en) 2020-04-09
CA2966765C (en) 2020-04-14
GT201700104A (es) 2018-11-27
JP2019014735A (ja) 2019-01-31
CN108064173A (zh) 2018-05-22
CO2017004976A2 (es) 2017-10-10
BR112017010481A8 (pt) 2023-04-11
AU2018211208A1 (en) 2018-08-16
WO2016081670A2 (en) 2016-05-26
CL2019001144A1 (es) 2019-07-19
US10183981B2 (en) 2019-01-22
EP3660041B1 (en) 2023-04-19
CN112494656A (zh) 2021-03-16
WO2016081670A3 (en) 2016-08-04
MX2020014120A (es) 2021-03-25
JP2018501203A (ja) 2018-01-18
JP6703068B2 (ja) 2020-06-03
KR102101136B1 (ko) 2020-04-14
TN2017000178A1 (en) 2018-10-19
EP3221343A2 (en) 2017-09-27
CA2966765A1 (en) 2016-05-26
KR20190069622A (ko) 2019-06-19
DOP2017000124A (es) 2017-08-15
PH12017500935A1 (en) 2017-11-27

Similar Documents

Publication Publication Date Title
AR102712A1 (es) Agonistas parciales del receptor de insulina
CL2017003404A1 (es) Compuestos antibacterianos
UY36179A (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagón
MX377610B (es) Agonistas del receptor de glucagon.
CL2016003075A1 (es) Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
MX2016012446A (es) Derivados de quinoxalina utiles como amortiguadaores de receptor del factor de crecimiento de fibroblastos (fgfr) cinasa.
CL2016001911A1 (es) Compuesto heterocíclico fusionado
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
CL2015003735A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
MX377534B (es) Compuestos para usarse en el tratamiento de hiperinsulinemia.
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
MX381544B (es) Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.
CL2015003584A1 (es) Compuestos nuevos para el tratamiento del cáncer.
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX372922B (es) Un derivado de la cromona como el antagonista del receptor de la dopamina d3 para su uso en el tratamiento del trastorno del espectro autista.
MX377995B (es) Moléculas de unión al receptor bag3 para uso como un medicamento.
MX2017014128A (es) 2-tiopirimidinonas.
BR112016028614A8 (pt) novos agonistas de ep4, composição farmacêutica compreendendo os mesmos e seu uso
CL2016002653A1 (es) Combinación farmacéutica que comprende brexpiprazol y nalmefeno; composición farmacéutica que los comprende; kit farmacéutico; y uso de la combinación para la prevención y tratamiento de un trastorno relacionado con sustancias como el alcohol.
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
ECSP17039183A (es) Agonistas parciales del receptor de insulina

Legal Events

Date Code Title Description
FB Suspension of granting procedure